<!doctype html><html><head><meta charset=utf-8><title>Hip fracture risk was reduced by 4 times when Vitamin D was added to SERMS</title>
<link rel=stylesheet href="/css/main.css?v=1748384346"><link rel=stylesheet href="/css/pagination.css?v=1748384346"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src=https://unpkg.com/lunr/lunr.js></script><script src=https://cdn.jsdelivr.net/npm/pako@2.1.0/dist/pako.min.js></script><script src="/js/search.js?v=1748384346"></script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><h1>Hip fracture risk was reduced by 4 times when Vitamin D was added to SERMS</h1><time>January 22, 2024</time><nav id=TableOfContents><ul><li><ul><li><ul><li><a href=#study-selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-agent-can-prevent-fracture-better-than-serms-treatment>Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:</a></li></ul></li></ul></li></ul></nav><hr><h4 id=study-selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-agent-can-prevent-fracture-better-than-serms-treatment>Study: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment:</h4><p><strong>based on the National Health Claims Database 2017-2019</strong></p><p>Osteoporos Int 2024 Jan 19. <a href=https://doi.org/10.1007/s00198-024-07022-7>doi: 10.1007/s00198-024-07022-7</a> <a href="https://www.deepdyve.com/lp/springer-journals/selective-estrogen-receptor-modulators-serms-with-vitamin-d-composite-FCTILqFMaH?key=springer%20">Can be viewed at DeepDyve 1 month free trial</a></p><p>Seong-Eun Byun 1, Hasung Kim 2, Seung Yun Lee 2, Sang-Min Kim 3</p><p><strong>4X reduction in hip fractures in those who happened to be prescribed<br>to take some amount of Vitamin D in addition to SERMS</strong></p><img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/png/hip-d.png alt=image width=600><p>With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.</p><p>Purpose: This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.</p><p>Methods: The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017-2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan-Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.</p><p>Results: The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio <span>[HR]</span>, 0.77; 95% confidence interval <span>[CI]</span>, 0.61-0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group.</p><p>Analysis for specific fractures showed a <strong>lower hazard of hip fracture in the SERM + VitD group (HR, 0.25</strong> ; 95% CI, 0.09-0.71; p = 0.009). No difference was observed between the groups regarding mortality.</p><p>Conclusion: The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.</p><h5 id=26-references>26 References</h5><ol><li><p>Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602 - DOI - PubMed</p></li><li><p>Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. <a href=https://doi.org/10.1007/s40980-020-00061-8>https://doi.org/10.1007/s40980-020-00061-8</a> - DOI - PubMed - PMC</p></li><li><p>Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 - DOI - PubMed</p></li><li><p>Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. <a href=https://doi.org/10.1016/j.afos.2020.11.007>https://doi.org/10.1016/j.afos.2020.11.007</a> - DOI - PubMed - PMC</p></li><li><p>Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. <a href=https://doi.org/10.1097/MCO>https://doi.org/10.1097/MCO</a> - DOI - PubMed - PMC</p></li><li><p>Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. <a href=https://doi.org/10.1007/s00198-017-3955-x>https://doi.org/10.1007/s00198-017-3955-x</a> - DOI - PubMed</p></li><li><p>Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. <a href=https://doi.org/10.1007/s00198-011-1868-7>https://doi.org/10.1007/s00198-011-1868-7</a> - DOI - PubMed - PMC</p></li><li><p>Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46 - DOI - PubMed</p></li><li><p>Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. <a href=https://doi.org/10.3349/ymj.2019.60.10.969>https://doi.org/10.3349/ymj.2019.60.10.969</a></p></li><li><p>Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52</p></li><li><p>Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. <a href=https://doi.org/10.1359/jbmr.2000.15.4.721>https://doi.org/10.1359/jbmr.2000.15.4.721</a> - DOI - PubMed</p></li><li><p>Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139 - DOI - PubMed</p></li><li><p>Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137 - DOI - PubMed</p></li><li><p>Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645</p></li><li><p>Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. <a href=https://doi.org/10.2147/CLEP.S164112>https://doi.org/10.2147/CLEP.S164112</a> - DOI - PubMed - PMC</p></li><li><p>Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639 - DOI - PubMed</p></li><li><p>Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264 - DOI - PubMed</p></li><li><p>LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. <a href=https://doi.org/10.1056/nejmoa2202106>https://doi.org/10.1056/nejmoa2202106</a> - DOI - PubMed - PMC</p></li><li><p>Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. <a href=https://doi.org/10.1016/j.maturitas.2020.06.016>https://doi.org/10.1016/j.maturitas.2020.06.016</a> - DOI - PubMed</p></li><li><p>Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. <a href=https://doi.org/10.1097/MD.0000000000011032>https://doi.org/10.1097/MD.0000000000011032</a> - DOI - PubMed</p></li><li><p>Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. <a href=https://doi.org/10.4162/nrp.2019.13.2.115>https://doi.org/10.4162/nrp.2019.13.2.115</a></p></li><li><p>Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358 - DOI - PubMed</p></li><li><p>Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. <a href=https://doi.org/10.6118/jmm.19193>https://doi.org/10.6118/jmm.19193</a> - DOI - PubMed - PMC</p></li><li><p>Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673 - DOI - PubMed - PMC</p></li><li><p>Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743 - DOI - PubMed - PMC</p></li><li><p>Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. <a href=https://doi.org/10.1016/S2213-8587(21)00345-4>https://doi.org/10.1016/S2213-8587(21)00345-4</a> - DOI - PubMed</p></li></ol></article></div></div><script src="/js/lightspa.js?v=1748384346"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1748384346",indexUrl:"/search/search_index.json.gz?v=1748384346"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/toc-sanitizer.js?v=1748384346"></script><script src="/js/search-results-panel.js?v=1748384346"></script><script src="/js/tiki-redirects.js?v=1748384346"></script></body></html>